NICE Enough? Watchdog's Basic Approach Is Sound, But More Transparency Is Urged

An independent report into how NICE values medicines concludes that the basis of its cost-effectiveness assessment is sound, but can be improved. And more transparency would help.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet